7-Methoxytryptamine

Last updated

7-Methoxytryptamine
7-Methoxytryptamine.svg
Clinical data
Other names7-Methoxy-T; 7-MeO-T; 7-OMe-T; PAL-533; PAL533
Drug class Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonin releasing agent
ATC code
  • None
Identifiers
  • 2-(7-methoxy-1H-indol-3-yl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C11H14N2O
Molar mass 190.246 g·mol−1
3D model (JSmol)
  • COC1=CC=CC2=C1NC=C2CCN
  • InChI=1S/C11H14N2O/c1-14-10-4-2-3-9-8(5-6-12)7-13-11(9)10/h2-4,7,13H,5-6,12H2,1H3
  • Key:ZUJIGHUQQNOCAM-UHFFFAOYSA-N

7-Methoxytryptamine (7-MeO-T or 7-methoxy-T; developmental code name PAL-533) is a serotonin receptor modulator and monoamine releasing agent of the tryptamine family. [1] [2] It is the 7-methoxy derivative of tryptamine. [1]

Contents

The drug acts as a full agonist of the serotonin 5-HT2A receptor, with an EC50 Tooltip half-maximal effective concentration of 496 nM and an Emax Tooltip maximal efficacy of 107%. [1] It shows 67-fold lower potency as a serotonin 5-HT2A receptor agonist compared to tryptamine itself. [1] In addition to its serotonin 5-HT2A receptor agonism, 7-methoxytryptamine is a serotonin releasing agent (SRA), with EC50 values for induction of monoamine release of 44.6 nM for serotonin, 2,118 nM for dopamine, and 5,600 nM for norepinephrine in rat brain synaptosomes. [1] The effects of 7-methoxytryptamine in rodents have been described. [3] [4]

Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. [5] [6] [7] [8] [9] [10] [11] However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans. [12] [6] [1] [11]

The chemical synthesis of 7-methoxytryptamine has been described. [1] [13] [14] [3] [15]

7-Methoxytryptamine was first described in the scientific literature by Ernst Späth and Edgar Lederer by 1931. [15] [16] Its pharmacology was subsequently assessed in greater detail in 2014. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, et al. (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorganic & Medicinal Chemistry Letters. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC   4211607 . PMID   25193229.
  2. ↑ Keup W (1970). "Structure-Activity Relationship among Hallucinogenic Agents". Origin and Mechanisms of Hallucinations. Boston, MA: Springer US. pp. 345–376. doi:10.1007/978-1-4615-8645-6_29. ISBN   978-1-4615-8647-0.
  3. 1 2 Kalir A, Balderman D, Edery H, Porath G (1967). "7‐Methoxyindole and its Derivatives". Israel Journal of Chemistry. 5 (4): 129–136. doi:10.1002/ijch.196700026. ISSN   0021-2148.
  4. ↑ Nichols DE, Glennon RA (1984). "Medicinal Chemistry and Structure-Activity Relationships of Hallucinogens". In Jacobs BL (ed.). Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives. New York: Raven Press. pp. 95–142. ISBN   978-0-89004-990-7. OCLC   10324237. 7-Methoxytryptamine displayed weak behavioral activity in animals (124). [...] The 6- and 7-methoxy derivatives of DMT, 71 and 72, respectively, display a low order of behavioral activity in animals (65,86,91,93,124). [...] The 6- and 7-methoxy derivatives [of DMT] are less active than either the 4- or 5-methoxy isomers.
  5. ↑ Jones RS (1982). "Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?". Progress in Neurobiology. 19 (1–2): 117–139. doi:10.1016/0301-0082(82)90023-5. PMID   6131482.
  6. 1 2 Shulgin A (1997). Tihkal: The Continuation. Transform Press. #53. T. ISBN   978-0-9630096-9-2 . Retrieved 17 August 2024. (with 250 mg, intravenously) "Tryptamine was infused intravenously over a period of up to 7.5 minutes. Physical changes included an increases in blood pressure, in the amplitude of the patellar reflex, and in pupillary diameter. The subjective changes are not unlike those seen with small doses of LSD. A point-by-point comparison between the tryptamine and LSD syndromes reveals a close similarity which is consistent with the hypothesis that tryptamine and LSD have a common mode of action."
  7. ↑ Nichols DE (2012). "Structure–activity relationships of serotonin 5-HT2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi: 10.1002/wmts.42 . ISSN   2190-460X.
  8. ↑ Nichols DE (2018). Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43. doi:10.1007/7854_2017_475. ISBN   978-3-662-55878-2. PMID   28401524.
  9. ↑ Prozialeck WC, Vogel WH (February 1979). "MAO inhibition and the effects of centrally administered LSD, serotonin, and 5-methoxytryptamine on the conditioned avoidance response in rats". Psychopharmacology. 60 (3): 309–310. doi:10.1007/BF00426673. PMID   108709. In contrast, MAO inhibition greatly increased brain levels of 5-HT and 5-MT (Prozialeck and Vogel, 1978). For instance, clorgyline and deprenyl increased brain levels of 5-HT 8.5-fold and 4.4-fold and of 5-MT 20-fold and 5-fold, respectively.
  10. ↑ Boess FG, Martin IL (1994). "Molecular biology of 5-HT receptors". Neuropharmacology. 33 (3–4): 275–317. doi:10.1016/0028-3908(94)90059-0. PMID   7984267.
  11. 1 2 Martin WR, Sloan JW (1970). "Effects of infused tryptamine in man". Psychopharmacologia. 18 (3): 231–237. doi:10.1007/BF00412669. PMID   4922520.
  12. ↑ Martin WR, Sloan JW (1977). "Pharmacology and Classification of LSD-like Hallucinogens". Drug Addiction II. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 305–368. doi:10.1007/978-3-642-66709-1_3. ISBN   978-3-642-66711-4. MARTIN and SLOAN (1970) found that intravenously infused tryptamine increased blood pressure, dilated pupils, enhanced the patellar reflex, and produced perceptual distortions. [...] Tryptamine, but not DMT, increases locomotor activity in the mouse, while both antagonize reserpine depression (V ANE et al., 1961). [...] In the rat, tryptamine causes backward locomotion, Straub tail, bradypnea and dyspnea, and clonic convulsions (TEDESCHI et al., 1959). [...] Tryptamine produces a variety of changes in the cat causing signs of sympathetic activation including mydriasis, retraction of nictitating membrane, piloerection, motor signs such as extension of limbs and convulsions and affective changes such as hissing and snarling (LAIDLAW, 1912). [...]
  13. ↑ Repke DB, Grotjahn DB, Shulgin AT (July 1985). "Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents". Journal of Medicinal Chemistry. 28 (7): 892–896. doi:10.1021/jm00145a007. PMID   4009612.
  14. ↑ Sóti F, Incze M, Kardos-Balogh Z, Kajtár-Peredy M, Szántay C (1993). "Synthesis of Vinca Alkaloids and Related Compounds. LXV. Preparation of 7-Methoxytryptamine". Synthetic Communications. 23 (12): 1689–1698. doi:10.1080/00397919308011267. ISSN   0039-7911.
  15. 1 2 Späth E, Lederer E (17 September 1930). "Synthesen von 4‐Carbolinen". Berichte der deutschen chemischen Gesellschaft (A and B Series). 63 (8): 2102–2111. doi:10.1002/cber.19300630839. ISSN   0365-9488.
  16. ↑ Manske RH (1 June 1931). "The synthesis of some indol derivatives". Canadian Journal of Research. 4 (6): 591–595. doi:10.1139/cjr31-047. ISSN   1923-4287.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.